Canaccord analyst Richard Close raised the firm’s price target on AdaptHealth (AHCO) to $14 from $13 and keeps a Buy rating on the shares. The firm said 4Q was a step forward in rebuilding investor confidence for Adapt as results showed revenue upside and 2025 guidance that has revenue and adj-EBITDA ranges bracketing both Canaccord and consensus prior estimates, and a respectable FCF range of $180-$220 million.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue